Dow Jones
33.002,38 -430,97 (-1,29%) Nasdaq
13.059,47 -248,31 (-1,87%) Nikkei 225
30.526,88 -711,06 (-2,28%) EUR/USD
1,0461 -0,0008 (-0,07%) Bitcoin EUR
26.204,62 -232,90 (-0,88%) CMC Crypto 200
584,33 -5,65 (-0,96%)
Valneva SE (0OB3.L)
| Chiusura precedente | 5,43 |
| Aperto | 0,00 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 36.707 |
| Capitalizzazione | 4,713M |
| Beta (5 anni mensile) | 0,93 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,71 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireValneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million
Saint Herblain (France), September 25, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®. Under this new one-year contract, the DoD will buy a minimum of $32 million worth of IXIARO® vaccines and has the possibility to purchase additional doses during the coming twelve months. Delive
- GlobeNewswire
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
Product sales more than doubled in the first half of 2023 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO® and DUKORAL® sales, both of which benefited from a continued recovery of the travel industry as well as from price increasesBringing total revenues to €73.7 million in the first half of 2023 Strong cash position of €204.4 million as at June 30, 2023 Excludes up to an additional $100 million made available as part of a recent upsized financing arrangemen
- GlobeNewswire
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Strong immune response shown in both children and adolescents one month after booster dose (month 19) in VLA15-221 studyPreviously observed high anamnestic antibody response in adults confirmedVLA15 well-tolerated in all age groups following booster dose Saint-Herblain (France) & New York, September 7, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine ca
